Recommendations From The 2023 International Evidence-Based Guideline For The Assessment And Management Of Polycystic Ovary Syndrome

The 2023 international guideline for the assessment and management of polycystic ovary syndrome (PCOS) recommends a comprehensive approach to diagnosis and treatment, including lifestyle changes, medication, and psychological support. The guideline, formulated by an international panel of experts, emphasizes early detection and management of associated risks such as diabetes, cardiovascular disease, and mental health issues. It provides 254 recommendations for managing PCOS, including patient empowerment, recognition of broader PCOS features, and evidence-based medical therapy. The guideline also suggests using total and free testosterone for diagnosing biochemical hyperandrogenism in PCOS, with hirsutism being a strong predictor of PCOS in adults. It recommends an OGTT test at 24-28 weeks gestation for all women with PCOS, regardless of BMI, due to increased risks of sleep apnea, endometrial hyperplasia, and cancer. The guideline suggests treatments such as lifestyle changes, medication, and laser hair removal to manage symptoms. It also identifies PCOS as a common condition that increases the risk of several health issues including cardiovascular disease, type 2 diabetes, and psychological disorders.